Roy-Chowdhuri Sinchita, Stewart John
From the Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston.
Arch Pathol Lab Med. 2016 Nov;140(11):1191-1199. doi: 10.5858/arpa.2016-0117-RA. Epub 2016 Jun 22.
Context .- As our understanding of genomic alterations underlying solid tumor malignancies continues to evolve, molecular testing of tumor samples is increasingly used to guide therapeutic management. Next-generation sequencing (NGS) provides a novel platform for the simultaneous screening of multiple genes using small amounts of DNA. Several recent studies have described NGS mutational analysis using cytologic specimens. The cytopathologist's role in specimen assessment and triaging is critical to effectively implementing NGS in routine cytology practice. Objectives .- To review the NGS experience and a variety of preanalytic factors that affect NGS success rates of cytologic specimens at our institution. Data Sources .- To evaluate cytology specimen adequacy rates for NGS, we reviewed a 14-month period of image-guided fine-needle aspiration and core needle biopsies, used for testing. In addition, we reviewed data from our previously published studies to evaluate preanalytic factors affecting NGS success in these specimens. Conclusions .- Identifying factors that affect NGS success rates in cytology specimens is crucial for a better understanding of specimen adequacy requirements and for proper use of limited-volume tissue samples. In our practice, which uses direct smears as well as cell block sections, NGS success rates in core needle biopsy and fine-needle aspiration samples are comparable. The chance of successful testing is further increased by procuring concurrent fine-needle aspiration and core needle biopsy samples. The type of glass slides used for direct smears and the method of tissue extraction affect our DNA yield. Validating a DNA input for cytology samples that is lower than that recommended by the manufacturer has significantly increased our NGS success rate.
随着我们对实体瘤恶性肿瘤潜在基因组改变的理解不断发展,肿瘤样本的分子检测越来越多地用于指导治疗管理。新一代测序(NGS)提供了一个使用少量DNA同时筛查多个基因的新平台。最近的几项研究描述了使用细胞学标本进行NGS突变分析。细胞病理学家在标本评估和分类中的作用对于在常规细胞学实践中有效实施NGS至关重要。目的:回顾我们机构在NGS方面的经验以及影响细胞学标本NGS成功率的各种分析前因素。数据来源:为了评估用于NGS的细胞学标本充足率,我们回顾了14个月期间用于检测的影像引导下细针穿刺和粗针活检。此外,我们回顾了我们之前发表的研究数据,以评估影响这些标本NGS成功的分析前因素。结论:识别影响细胞学标本NGS成功率的因素对于更好地理解标本充足性要求和正确使用有限体积的组织样本至关重要。在我们使用直接涂片和细胞块切片的实践中,粗针活检和细针穿刺样本的NGS成功率相当。同时采集细针穿刺和粗针活检样本可进一步提高成功检测的机会。用于直接涂片的载玻片类型和组织提取方法会影响我们的DNA产量。验证低于制造商推荐的细胞学样本DNA输入量显著提高了我们的NGS成功率。